Afatinib Recruiting Phase 2 Trials for Non-small-cell Lung Cancer With Somatic EGFR Mutations Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02488694Maintaining ERBB Blockade in EGFR-mutated Lung Cancer